Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2 | drbeen
Author declares no conflict of interest.
Get free trial
with access to all our lectures
DrBeen Logo

no credit card required

My Notes

Become a member to create study notes.
Sign up for free trial
Merck’s Molnupiravir (EIDD-281) Effective Against SARS-COV-2 Duration: 1751
Microbiology / Virology

Learning Objectives

Merck has a new drug molecule for SARS-COV-2. It is named Molnupiravir or EIDD-2801. We will discuss the following topics about this drug.


  1. Need for this anti-viral drug to be used with Remdesivir.
  2. History of the EIDD-2801.
  3. Trial for phase II and phase III.
  4. Route of administration.
  5. Drug properties.
  6. Mechanism of action.
  7. Results in mouse studies.
  8. Therapeutic index.


Dr. Mobeen Syed

Dr. Mobeen Syed

Mobeen Syed M.D, MS Graduated from King Edward Medical University. Entrepreneur, Medical Educator, CEO and founder of Drbeen corp.

Videos in this series